The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Click here to watch it, free.
Robert W. Duggan net worth and biography

Robert Duggan Biography and Net Worth

Robert W. Duggan joined the Board of Directors in December 2019 and has been the Executive Chairman our Board since February 2020.  Mr. Duggan has served as our Chief Executive Officer since April 2020.

Since 2015, Mr. Duggan has also been the Founder and CEO of Duggan Investments, a venture capital and equity investment firm.  His firm’s investments primarily focus on patient-friendly breakthrough solutions to complex diseases of aging.

From 2008 to 2015, Mr. Duggan was Chairman, CEO, and the largest investor in Pharmacyclics, Inc., a patient-friendly, science-based, employee-driven developer of small-molecule medicines for the treatment of certain cancers.  Mr. Duggan led both the multimillion-dollar collaboration and license deal for ibrutinib (later marketed as IMBRUVICA®) with Johnson & Johnson in 2011, and the subsequent sale of Pharmacyclics to AbbVie Inc. in 2015.  The acquisition of Pharmacyclics by AbbVie for approximately $21B remains one of the largest transactions to have occurred in the pharmaceutical and biotechnology industries.

From 1990 to 2003, Mr. Duggan was Chairman of the Board of Directors of Computer Motion, Inc., a groundbreaking robotic surgery company that helped change the way in which many surgical procedures are performed around the world with the assistance of its minimally invasive, robotics-based surgical systems. From 1997 to 2003, Mr. Duggan also served as CEO of Computer Motion.  In June 2003, Computer Motion merged with Intuitive Surgical, Inc.  From the completion of the merger in 2003 until 2011, Mr. Duggan served on the Board of Directors of Intuitive Surgical.

Mr. Duggan received a US Congressional Medal of Merit from Congressman Dr. Ron Paul in 1985.  In 2000, he was named a Knight of the Legion D’Honor by President Jacques Chirac of France.

Beyond Summit, Mr. Duggan is currently the Chairman of the Board at Pulse BioSciences, Inc., and is also a member of the University of California at Santa Barbara Foundation Board of Trustees.  Mr. Duggan has also funded two Chairs in Mathematical, Life, and Physical Sciences, as well as a Chair in Religious Studies at the University of California at Santa Barbara.

What is Robert W. Duggan's net worth?

The estimated net worth of Robert W. Duggan is at least $524.98 million as of August 16th, 2022. Mr. Duggan owns 162,532,792 shares of Summit Therapeutics stock worth more than $524,980,918 as of January 29th. This net worth evaluation does not reflect any other investments that Mr. Duggan may own. Learn More about Robert W. Duggan's net worth.

How old is Robert W. Duggan?

Mr. Duggan is currently 79 years old. There are 6 older executives and no younger executives at Summit Therapeutics. Learn More on Robert W. Duggan's age.

How do I contact Robert W. Duggan?

The corporate mailing address for Mr. Duggan and other Summit Therapeutics executives is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. Summit Therapeutics can also be reached via phone at 617-514-7149 and via email at [email protected] Learn More on Robert W. Duggan's contact information.

Has Robert W. Duggan been buying or selling shares of Summit Therapeutics?

Robert W. Duggan has not been actively trading shares of Summit Therapeutics over the course of the past ninety days. Most recently, on Tuesday, August 16th, Robert W. Duggan bought 94,849,203 shares of Summit Therapeutics stock. The stock was acquired at an average cost of $0.97 per share, with a total value of $92,003,726.91. Following the completion of the transaction, the chief executive officer now directly owns 162,532,792 shares of the company's stock, valued at $157,656,808.24. Learn More on Robert W. Duggan's trading history.

Who are Summit Therapeutics' active insiders?

Summit Therapeutics' insider roster includes Robert Duggan (CEO), and Maky Zanganeh (COO). Learn More on Summit Therapeutics' active insiders.

Are insiders buying or selling shares of Summit Therapeutics?

In the last year, Summit Therapeutics insiders bought shares 2 times. They purchased a total of 94,860,760 shares worth more than $92,014,937.20. The most recent insider tranaction occured on August, 16th when CFO Ankur Dhingra bought 11,557 shares worth more than $11,210.29. Insiders at Summit Therapeutics own 87.5% of the company. Learn More about insider trades at Summit Therapeutics.

Information on this page was last updated on 8/16/2022.

Robert W. Duggan Insider Trading History at Summit Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2022Buy94,849,203$0.97$92,003,726.91162,532,792View SEC Filing Icon  
5/12/2021Buy11,365,921$5.24$59,557,426.0467,662,454View SEC Filing Icon  
See Full Table

Robert W. Duggan Buying and Selling Activity at Summit Therapeutics

This chart shows Robert W Duggan's buying and selling at Summit Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Summit Therapeutics Company Overview

Summit Therapeutics logo
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $3.23
Low: $3.08
High: $3.60

50 Day Range

MA: $3.34
Low: $0.68
High: $5.41

2 Week Range

Now: $3.23
Low: $0.66
High: $5.78


2,788,800 shs

Average Volume

3,486,111 shs

Market Capitalization

$650.27 million

P/E Ratio


Dividend Yield



Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
click here now to get all the chilling details.